Delivery Order SPE2DB24D8002-SPE2DB24FJMQM

Award Date 7/23/24
Potential Completion Date 7/24/24
Potential Value $1.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The $2,073.16 firm fixed-price contract is for the delivery of 100 units of the prescription medication Vyvanse 40 mg capsules. This award falls under Dakota Drug, Inc.'s larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT...
The Defense Logistics Agency (DLA) awarded a $1,184.36 firm fixed-price delivery order contract to Dakota Drug, Inc., a small disadvantaged business. The contract is for the delivery of VYVANSE 30 MG CAPSULE 100S, a prescription medication. This delivery order falls under Dakota Drug, Inc.'s $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which procures commercial medical equipment, accessories, consumables, and medical...
This federal contract award, with a ceiling value of $2,122.33, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is a delivery order under the DLA Troop Support Medical's ECAT Generation V Program, an Indefinite Delivery Contract (IDC) with a maximum value of $999,999,999.00 and a performance period through December 31, 2025. The contract is for the delivery of 4,562,763,308 units of Vyvanse 30 mg capsules, a...
This federal contract award was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The $2,199.11 firm fixed-price delivery order is for the supply of 100 capsules of the prescription drug Vyvanse 40 mg. The award is associated with a larger Indefinite Delivery Contract (IDC) identified as SPE2DB24D8001, valued at $999,999,999.00, which allows Dakota Drug, Inc. to provide a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4,563,714,305 units of Vyvanse 40 mg capsules. The contract has a ceiling value of $2,237.18 and a completion date of February 21, 2024. This is a firm fixed-price delivery order contract, and there is no set-aside designation. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, holding a single-award...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,201.92, is for the delivery of 100 units of the prescription medication Vyvanse 30 mg capsules. It is a firm fixed-price delivery order contract with a completion date of March 5, 2025. The award is associated with a larger Indefinite Delivery Contract (IDC) held by Dakota Drug, Inc., identified as SPE2DB24D8001 and valued at...
This federal contract award, valued at $1,461.18, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 100 units of the medication VYVANSE 30 MG CAPSULE. The contract has a firm fixed price pricing type and an ultimate completion date of August 15, 2024. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. This contract...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The award, valued at $1,341.22, is for the provision of 10 mg Vyvanse capsules (100 count) to support medical supply chain operations for the U.S. Armed Forces. The contract has a completion date of May 15, 2024 and was awarded on May 14, 2024 without the use of a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $4,783.81 firm fixed-price contract is for the delivery of VYVANSE 40 MG CAPSULE 100S, a pharmaceutical product. The contract has a period of performance through February 24, 2025. Dakota Drug, Inc. is a key supplier to the DLA, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) as part of the DLA Troop Support Medical's ECAT...
This federal contract award, identified as SPE2DX15D8002|SPE2DX23F2XH9, was granted to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA) Troop Support Medical division. The $1,011.24 firm fixed-price delivery order is for the provision of 4560939520 VYVANSE 40 MG CAPSULE 100S, a prescription medication. This contract is not set aside and is part of Dakota Drug, Inc.'s larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA,...
  • SPE2DB24D8002
    Indefinite Delivery Contract
  • SPE2DB24D8002-SPE2DB24FJMQM
    Delivery Order

The Defense Logistics Agency (DLA) awarded a $1,461.18 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, to provide 4,565,228,290 units of the prescription medication Vyvanse 50 mg capsules. This order falls under Dakota Drug's Indefinite Delivery Contract (IDC) SPE2DB24D8001 with DLA Troop Support Medical, a $999,999,999.00 single-award contract that enables the company to supply a range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations through the ECAT Generation V Program. The contract does not have a set-aside designation, but Dakota Drug maintains its status as a small disadvantaged business. This award demonstrates the company's crucial role as a prime contractor in delivering critical medications to military treatment facilities.

Generated 10/22/24, 9:25 AM